In June of 2020, the preliminary report from the RECOVERY clinical trial demonstrated that 10 days of dexamethasone had a significant mortality benefit in hospitalized COVID-19 patients (NEJM JW Infect Dis Sep 2020 and N Engl J Med 2020 Jul 17; [e-pub]). These findings resulted in the halting of other clinical trials evaluating steroids in this population for lack of equipoise. The World Health Organization had also planned a prospective meta-analysis of studies evaluating the role of steroids in severe COVID-19, including data from RECOVERY. What do the data to date tell us?
展开▼
